Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Diabetes, as defined by the World Health Organization, represents a collection of metabolic diseases characterized primarily by hyperglycemia, which can ...

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...

Liver issues, including a buildup of fat in the liver, occur before the onset of neuromuscular disease, per a study in a mouse model of SMA.

The distinct population of endothelial cells that line blood vessels in the insulin-producing "islets" of the human pancreas ...

Targeting mitochondrial retrograde signaling may therefore be promising in the treatment or prevention of metabolic disorders ...

Severe abdominal pain was one of the first signs of pancreatic cancer for Paula Rowland. She ignored it for months. After ...

A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the deadliest cancers.

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...